Galera Therapeutics Faces Nasdaq Delisting
Ticker: GRTX · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1563577
Sentiment: bearish
Topics: delisting, compliance, nasdaq
TL;DR
Nasdaq's kicking Galera off the exchange due to low stock price.
AI Summary
Galera Therapeutics, Inc. filed an 8-K on August 31, 2024, to report its failure to meet the continued listing standards of the Nasdaq Capital Market. The company was notified on August 29, 2024, that it was not in compliance with the minimum bid price requirement. Consequently, Galera Therapeutics' common stock is subject to delisting from the Nasdaq Capital Market.
Why It Matters
This filing indicates a significant financial distress for Galera Therapeutics, as its stock is no longer meeting exchange requirements, potentially impacting investor confidence and future funding.
Risk Assessment
Risk Level: high — The company is facing delisting from a major stock exchange, indicating severe financial and operational challenges.
Key Numbers
- 001-39114 — SEC File Number (Identifies the company's filings with the SEC.)
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Stock Exchange
- August 31, 2024 (date) — Report Date
- August 29, 2024 (date) — Notification Date
FAQ
What specific Nasdaq listing rule did Galera Therapeutics fail to satisfy?
Galera Therapeutics failed to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
When was Galera Therapeutics notified of its non-compliance?
Galera Therapeutics was notified of its non-compliance on August 29, 2024.
What is the consequence of failing to meet Nasdaq's continued listing standards?
The consequence is that the company's common stock is subject to delisting from the Nasdaq Capital Market.
What is the exact date of the report filed by Galera Therapeutics?
The exact date of the report is August 31, 2024.
What is the principal executive office address of Galera Therapeutics?
The principal executive office address is 45 Liberty Blvd #230, Malvern, PA 19355.
Filing Stats: 768 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2024-09-04 07:01:02
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share GRTX OTC Pink M
Filing Documents
- d854745d8k.htm (8-K) — 24KB
- 0001193125-24-212627.txt ( ) — 143KB
- grtx-20240831.xsd (EX-101.SCH) — 2KB
- grtx-20240831_lab.xml (EX-101.LAB) — 18KB
- grtx-20240831_pre.xml (EX-101.PRE) — 11KB
- d854745d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GALERA THERAPEUTICS, INC. Date: September 4, 2024 By: /s/ J. Mel Sorensen, M.D. J. Mel Sorensen, M.D. President and Chief Executive Officer